U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07561723) titled 'IMP3-saRNA Vaccine in Advanced NSCLC' on April 25.
Brief Summary: This is an open-label, single-arm, non-randomized, single-center, prospective phase 1 clinical trial. The study will evaluate the safety, tolerability, and preliminary antitumor activity of IMP3-saRNA (YMN-136) vaccine in patients with advanced non-small cell lung cancer.
IMP3-saRNA (YMN-136) is a vaccine product prepared from IMP3 self-amplifying RNA and lipid nanoparticles. The study will enroll patients with histologically or cytologically confirmed non-small cell lung cancer who have failed, are intolerant to, or refuse standard treatment, and whose tumor tissue is...